Introduction to Reduces Exacerbations

What is/are Reduces Exacerbations?

Reduces Exacerbations - For the patient, controller inhaler adherence monitoring with feedback increases adherence and reduces exacerbations in adults3 and children4 with asthma. ^[1] Nintedanib slows disease progression and reduces exacerbations in idiopathic pulmonary fibrosis (IPF). ^[2] Rationale The macrolide antibiotic, azithromycin, reduces exacerbations in adults with persistent symptomatic asthma. ^[3] Self-care improves quality of life, and reduces exacerbations and mortality risk in people with chronic obstructive pulmonary disease (COPD). ^[4]

improves lung function

Objective: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma. ^[1] Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma. ^[2] BackgroundInhibition of interleukin (IL)-13, a Type 2 inflammatory mediator in asthma, improves lung function and reduces exacerbations; however, more effective therapies are needed. ^[3] INTERPRETATION In uncontrolled asthma, addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting β2-agonist therapy improves lung function and reduces exacerbations. ^[4] Negative pressure ventilation (NPV), when used as an adjuvant to pulmonary rehabilitation, improves lung function, increases exercise capacity, and reduces exacerbations. ^[5]

severe uncontrolled eosinophilic

Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptoms for patients with severe, uncontrolled eosinophilic asthma. ^[1]

Significantly Reduces Exacerbations

BACKGROUND AND OBJECTIVE Treatment with mepolizumab in severe eosinophilic asthma (SEA) significantly reduces exacerbations with modest improvements in symptom control and spirometry. ^[1] Objective: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma. ^[2] Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma. ^[3]

Therapy Reduces Exacerbations

Long‐term macrolide therapy reduces exacerbations of chronic respiratory diseases, but its effects on the prevention of pneumonia have not been determined. ^[1] Inhaled maintenance therapy reduces exacerbations. ^[2]

Azithromycin Reduces Exacerbations

78] p Conclusion: Long-term treatment with azithromycin reduces exacerbations, regardless of whether the patient has eosinophilic, non-eosinophilic or severe asthma. ^[1] Discussion Maintenance use of azithromycin reduces exacerbations in patients with eosinophilic, noneosinophilic and severe asthma. ^[2]